Levonadifloxacin

Levonadifloxacin ((S) - (-) -Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544) -susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes[1].

Product Specifications

CAS Number

[154357-42-3]

Product Name Alternative

(S) - (-) -Nadifloxacin; WCK 771

UNSPSC

12352005

Hazard Statement

H301

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/levonadifloxacin.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CN2[C@@H](C)CCC3=C2C(C1=O)=CC(F)=C3N4CCC(O)CC4)O

Molecular Formula

C19H21FN2O4

Molecular Weight

360.38

Precautions

H301

References & Citations

[1]Dubois J, et al. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019 Dec;68 (12) :1716-1722. |[2]Bhagwat SS, et al. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63 (8) :e00909-19.